Norma E. Farrow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Norma E. Farrow has a total of 195 co-authors. Here are the top co-authors by number of shared publications:
Deborah B. Hobson
Department of Surgery Johns Hopkins University School of Medicine Baltimore MD
9 shared publicationsPeggy S. Kraus
Department of Pharmacy The Johns Hopkins Hospital Baltimore MD
9 shared publicationsDauryne L. Shaffer
Department of Surgery Johns Hopkins University School of Medicine Baltimore MD
8 shared publicationsGeorgia M. Beasley
Duke Cancer Institute Durham North Carolina USA
8 shared publicationsMichael B. Streiff
Division of Hematology, Department of Medicine Johns Hopkins University School of Medicine Baltimore MD
8 shared publicationsVictor O. Popoola
Department of Biostatistics Johns Hopkins Bloomberg School of Public Health Baltimore MD
8 shared publications
Latest Publications
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2600005
Patient Engagement With an Electronic Patient-Reported Outcomes Tool Evaluating Hospital Discharge Readiness After Cancer Surgery
PURPOSE: Patients undergoing cancer surgery often face complex, multidisciplinary needs related to recovery and discharge. The aim of this study was to develop and assess the adoption of an electronic patient-reported outcomes (ePRO) tool, Goals to Discharge (G2D), to improve discharge planning and recovery following colorectal and thoracic cancer surgeries. METHODS: We developed the G2D tool using a mixed-methods approach incorporating feedback from patients, clinicians, and stakeholders. Survey items were selected through a stepwise process aligned with Enhanced Recovery After Surgery pathways. Hospitalized patients recovering from colorectal or thoracic surgeries at a tertiary cancer center were prompted to complete the G2D tool on postoperative day 1 until discharge. Adoption factors were analyzed for associations with patient engagement and postoperative length of stay (LOS). RESULTS: Among 3,878 patients, the G2D tool had an adoption rate of 31% (1,190 patients with at least 1 survey response). Factors such as age, American Society of Anesthesia (ASA) score, primary language, and prolonged recovery room stays influenced adoption. Respondents to the G2D tool had a 3.7% reduction in the risk of prolonged LOS compared with nonrespondents ([95% CI, 0.84 to 6.5]; P = .011). CONCLUSION: The G2D ePRO tool enhanced communication between patients and clinical teams, contributing to improved discharge planning and recovery. Respondents to the tool had a significantly lower risk of prolonged hospital stays after surgery. Further research is needed to refine digital discharge tools and explore strategies for optimizing recovery preparation.
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2600005
Patient Engagement With an Electronic Patient-Reported Outcomes Tool Evaluating Hospital Discharge Readiness After Cancer Surgery
PURPOSE: Patients undergoing cancer surgery often face complex, multidisciplinary needs related to recovery and discharge. The aim of this study was to develop and assess the adoption of an electronic patient-reported outcomes (ePRO) tool, Goals to Discharge (G2D), to improve discharge planning and recovery following colorectal and thoracic cancer surgeries. METHODS: We developed the G2D tool using a mixed-methods approach incorporating feedback from patients, clinicians, and stakeholders. Survey items were selected through a stepwise process aligned with Enhanced Recovery After Surgery pathways. Hospitalized patients recovering from colorectal or thoracic surgeries at a tertiary cancer center were prompted to complete the G2D tool on postoperative day 1 until discharge. Adoption factors were analyzed for associations with patient engagement and postoperative length of stay (LOS). RESULTS: Among 3,878 patients, the G2D tool had an adoption rate of 31% (1,190 patients with at least 1 survey response). Factors such as age, American Society of Anesthesia (ASA) score, primary language, and prolonged recovery room stays influenced adoption. Respondents to the G2D tool had a 3.7% reduction in the risk of prolonged LOS compared with nonrespondents ([95% CI, 0.84 to 6.5]; P = .011). CONCLUSION: The G2D ePRO tool enhanced communication between patients and clinical teams, contributing to improved discharge planning and recovery. Respondents to the tool had a significantly lower risk of prolonged hospital stays after surgery. Further research is needed to refine digital discharge tools and explore strategies for optimizing recovery preparation.
- 2 October 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (9) , 1564-1571
Use of a Checkbox Format for Electronic Remote Symptom Monitoring After Surgery
PURPOSE: Comparative studies demonstrate that patients who use electronic patient-reported outcomes (ePROs) experience better outcomes; however, research comparing ePRO designs to determine optimal strategies for routine clinical practice is limited. We aimed to determine the impact of a novel checkbox format for presenting items in a postoperative symptom-assessment ePRO tool. METHODS: Patients undergoing prostatectomy, nephrectomy, mastectomy, hysterectomy, or thyroidectomy at a tertiary cancer hospital ambulatory surgery center through July 2024 were included. All patients were assigned the ePRO tool for 10 days postoperatively to assess surgical recovery. Historically, patients were asked to rate severity of all symptoms in the tool. An updated checkbox format was then implemented that asked if symptoms were present (yes/no) before eliciting qualitative severity ratings only for selected symptoms. An interrupted time-series design was used to compare patient engagement and psychometric properties before and after implementation of the checkbox format. RESULTS: 31,702 patients undergoing 38,929 operations were assigned the ePRO tool with (n = 17,432) or without (n = 21,497) the checkbox format. Without checkboxes, 75% of patients completed at least one questionnaire; mean completion time was 2 minutes. With checkboxes, completion rates improved by an adjusted absolute difference of 13% (95% CI, 12% to 14%; P < .001) and completion times decreased by 44 seconds (95% CI, 42 to 46; P < .001). Symptom scores were lower in the checkbox group and had better correlation with known predictors. CONCLUSION: Presenting ePRO items in a conditional checkbox format improved patient engagement, reduced survey burden, and was associated with better psychometric properties. The checkbox format should be standard for ePRO delivery in settings such as after surgery, where patients are likely to report only a subset of possible symptoms.
- 2 October 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (9) , 1564-1571
Use of a Checkbox Format for Electronic Remote Symptom Monitoring After Surgery
PURPOSE: Comparative studies demonstrate that patients who use electronic patient-reported outcomes (ePROs) experience better outcomes; however, research comparing ePRO designs to determine optimal strategies for routine clinical practice is limited. We aimed to determine the impact of a novel checkbox format for presenting items in a postoperative symptom-assessment ePRO tool. METHODS: Patients undergoing prostatectomy, nephrectomy, mastectomy, hysterectomy, or thyroidectomy at a tertiary cancer hospital ambulatory surgery center through July 2024 were included. All patients were assigned the ePRO tool for 10 days postoperatively to assess surgical recovery. Historically, patients were asked to rate severity of all symptoms in the tool. An updated checkbox format was then implemented that asked if symptoms were present (yes/no) before eliciting qualitative severity ratings only for selected symptoms. An interrupted time-series design was used to compare patient engagement and psychometric properties before and after implementation of the checkbox format. RESULTS: 31,702 patients undergoing 38,929 operations were assigned the ePRO tool with (n = 17,432) or without (n = 21,497) the checkbox format. Without checkboxes, 75% of patients completed at least one questionnaire; mean completion time was 2 minutes. With checkboxes, completion rates improved by an adjusted absolute difference of 13% (95% CI, 12% to 14%; P < .001) and completion times decreased by 44 seconds (95% CI, 42 to 46; P < .001). Symptom scores were lower in the checkbox group and had better correlation with known predictors. CONCLUSION: Presenting ePRO items in a conditional checkbox format improved patient engagement, reduced survey burden, and was associated with better psychometric properties. The checkbox format should be standard for ePRO delivery in settings such as after surgery, where patients are likely to report only a subset of possible symptoms.
- 17 September 2022
- Published by Wiley in Journal of Surgical Oncology
- Vol. 127 (1) , 140-147
Regional control after precision lymph node dissection for clinically evident melanoma metastasis
Introduction: Completion lymph node dissection (CLND) for microscopic lymph node metastases has been replaced by observation; however, CLND is standard for clinically detectable nodal metastases (cLN). CLND has high morbidity, which may be reduced by excision of only the cLN (precision lymph node dissection [PLND]). We hypothesized that same‐basin recurrence risk would be low after PLND.Methods: Retrospective review at four tertiary care hospitals identified patients who underwent PLND. The primary outcome was 3‐year cumulative incidence of isolated same‐basin recurrence.Results: Twenty‐one patients underwent PLND for cLN without synchronous distant metastases. Reasons for forgoing CLND included patient preference (n = 11), comorbidities (n = 5), imaging indeterminate for distant metastases (n = 2), partial response to checkpoint blockade (n = 1), or not reported (n = 2). A median of 2 nodes (range: 1–6) were resected at PLND, and 68% contained melanoma. Recurrence was observed in 33% overall. Only 1 patient (5%) developed an isolated same‐basin recurrence. Cumulative incidences at 3 years were 5.0%, 17.3%, and 49.7% for isolated same‐basin recurrence, any same‐basin recurrence, and any recurrence, respectively. Complications from PLND were reported in 1 patient (5%).Conclusions: These pilot data suggest that PLND may provide adequate regional disease control with less morbidity than CLND. These data justify prospective evaluation of PLND in select patients.
- 17 September 2022
- Published by Wiley in Journal of Surgical Oncology
- Vol. 127 (1) , 140-147
Regional control after precision lymph node dissection for clinically evident melanoma metastasis
Introduction: Completion lymph node dissection (CLND) for microscopic lymph node metastases has been replaced by observation; however, CLND is standard for clinically detectable nodal metastases (cLN). CLND has high morbidity, which may be reduced by excision of only the cLN (precision lymph node dissection [PLND]). We hypothesized that same‐basin recurrence risk would be low after PLND.Methods: Retrospective review at four tertiary care hospitals identified patients who underwent PLND. The primary outcome was 3‐year cumulative incidence of isolated same‐basin recurrence.Results: Twenty‐one patients underwent PLND for cLN without synchronous distant metastases. Reasons for forgoing CLND included patient preference (n = 11), comorbidities (n = 5), imaging indeterminate for distant metastases (n = 2), partial response to checkpoint blockade (n = 1), or not reported (n = 2). A median of 2 nodes (range: 1–6) were resected at PLND, and 68% contained melanoma. Recurrence was observed in 33% overall. Only 1 patient (5%) developed an isolated same‐basin recurrence. Cumulative incidences at 3 years were 5.0%, 17.3%, and 49.7% for isolated same‐basin recurrence, any same‐basin recurrence, and any recurrence, respectively. Complications from PLND were reported in 1 patient (5%).Conclusions: These pilot data suggest that PLND may provide adequate regional disease control with less morbidity than CLND. These data justify prospective evaluation of PLND in select patients.
- Open Access
- 1 September 2022
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (18) , e027119
Alert‐Triggered Patient Education Versus Nurse Feedback for Nonadministered Venous Thromboembolism Prophylaxis Doses: A Cluster‐Randomized Controlled Trial
Background: Many hospitalized patients are not administered prescribed doses of pharmacologic venous thromboembolism prophylaxis. Methods and Results: In this cluster‐randomized controlled trial, all adult non–intensive care units (10 medical, 6 surgical) in 1 academic hospital were randomized to either a real‐time, electronic alert–triggered, patient‐centered education bundle intervention or nurse feedback intervention to evaluate their effectiveness for reducing nonadministration of venous thromboembolism prophylaxis. Primary outcome was the proportion of nonadministered doses of prescribed pharmacologic prophylaxis. Secondary outcomes were proportions of nonadministered doses stratified by nonadministration reasons (patient refusal, other). To test our primary hypothesis that both interventions would reduce nonadministration, we compared outcomes pre‐ versus postintervention within each cohort. Secondary hypotheses were tested comparing the effectiveness between cohorts. Of 11 098 patient visits, overall dose nonadministration declined significantly after the interventions (13.4% versus 9.2%; odds ratio [OR], 0.64 [95% CI, 0.57–0.71]). Nonadministration decreased significantly ( P P =0.03) and refused doses ( P =0.003) compared with nurse feedback (OR, 1.28 [95% CI, 1.0–1.61]; P =0.03 for interaction). Conclusions: Information technology strategies like the alert‐triggered, targeted patient‐centered education bundle, and nurse‐focused audit and feedback can improve venous thromboembolism prophylaxis administration. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03367364.
- 1 September 2022
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (18) , e027119
Open AccessAlert‐Triggered Patient Education Versus Nurse Feedback for Nonadministered Venous Thromboembolism Prophylaxis Doses: A Cluster‐Randomized Controlled Trial
Background: Many hospitalized patients are not administered prescribed doses of pharmacologic venous thromboembolism prophylaxis. Methods and Results: In this cluster‐randomized controlled trial, all adult non–intensive care units (10 medical, 6 surgical) in 1 academic hospital were randomized to either a real‐time, electronic alert–triggered, patient‐centered education bundle intervention or nurse feedback intervention to evaluate their effectiveness for reducing nonadministration of venous thromboembolism prophylaxis. Primary outcome was the proportion of nonadministered doses of prescribed pharmacologic prophylaxis. Secondary outcomes were proportions of nonadministered doses stratified by nonadministration reasons (patient refusal, other). To test our primary hypothesis that both interventions would reduce nonadministration, we compared outcomes pre‐ versus postintervention within each cohort. Secondary hypotheses were tested comparing the effectiveness between cohorts. Of 11 098 patient visits, overall dose nonadministration declined significantly after the interventions (13.4% versus 9.2%; odds ratio [OR], 0.64 [95% CI, 0.57–0.71]). Nonadministration decreased significantly ( P P =0.03) and refused doses ( P =0.003) compared with nurse feedback (OR, 1.28 [95% CI, 1.0–1.61]; P =0.03 for interaction). Conclusions: Information technology strategies like the alert‐triggered, targeted patient‐centered education bundle, and nurse‐focused audit and feedback can improve venous thromboembolism prophylaxis administration. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03367364.
- 15 August 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (11) , e29884
Examining the role of wide excision margins in pediatric melanoma: A National Cancer Database analysis
Background: Although adult guidelines are often applied to children, age‐specific surgical margins have not been defined for pediatric melanoma.Procedure: Patients 1 cm) or narrow (≤1 cm) excision. Unadjusted overall survival (OS) was compared using the Kaplan–Meier method and log‐rank test. Multivariable Cox proportional hazard models were used to estimate the effect of excision margin on OS after adjustment for available covariates.Results: In total, 2081 patients met study criteria: 1338 (64.3%) patients underwent wide excision whereas 743 (35.7%) underwent narrow excision. Unadjusted OS was improved in the narrow‐excision group (log‐rank p = .01), which was consistent among patients with thicker (>1 mm) and thinner (≤1 mm) tumors. After adjustment for patient and tumor characteristics, we found no evidence of a difference in OS for patients who underwent narrow excision compared to patients who underwent wide excision (adjusted hazard ratio 0.57, 95% confidence interval 0.32–1.01, p = .053). There was no interaction between excision margin width and Breslow depth (p = .85), indicating that the effect of excision margin width on OS does not differ based on Breslow depth.Conclusions: In this analysis, wide excision (>1 cm) does not appear to be associated with improved survival in children with melanoma regardless of tumor characteristics. Although further studies are needed to define optimal excision margins in pediatric melanoma, this study suggests that more narrow margins (≤1 cm) may be acceptable.
- 15 August 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (11) , e29884
Examining the role of wide excision margins in pediatric melanoma: A National Cancer Database analysis
Background: Although adult guidelines are often applied to children, age‐specific surgical margins have not been defined for pediatric melanoma.Procedure: Patients 1 cm) or narrow (≤1 cm) excision. Unadjusted overall survival (OS) was compared using the Kaplan–Meier method and log‐rank test. Multivariable Cox proportional hazard models were used to estimate the effect of excision margin on OS after adjustment for available covariates.Results: In total, 2081 patients met study criteria: 1338 (64.3%) patients underwent wide excision whereas 743 (35.7%) underwent narrow excision. Unadjusted OS was improved in the narrow‐excision group (log‐rank p = .01), which was consistent among patients with thicker (>1 mm) and thinner (≤1 mm) tumors. After adjustment for patient and tumor characteristics, we found no evidence of a difference in OS for patients who underwent narrow excision compared to patients who underwent wide excision (adjusted hazard ratio 0.57, 95% confidence interval 0.32–1.01, p = .053). There was no interaction between excision margin width and Breslow depth (p = .85), indicating that the effect of excision margin width on OS does not differ based on Breslow depth.Conclusions: In this analysis, wide excision (>1 cm) does not appear to be associated with improved survival in children with melanoma regardless of tumor characteristics. Although further studies are needed to define optimal excision margins in pediatric melanoma, this study suggests that more narrow margins (≤1 cm) may be acceptable.
- 17 November 2021
- Published by Wiley in Journal of Surgical Oncology
- Vol. 125 (4) , 712-718
How much time is enough? Sentinel lymph node mapping time depends on the radiotracer agent
Background: In 2014, technetium‐99m tilmanocept (TcTM) replaced technetium‐99m sulfur colloid (TcSC) as the standard lymphoscintigraphy (LS) mapping agent in melanoma patients undergoing sentinel lymph node biopsy (SLNB). The aim of this study was to examine differences in mapping time, intra‐operative identification of sentinel lymph node (SLN), and false negative rate (FNR) between patients who underwent SLNB with TcTM compared to TcSC.Methods: Patients who underwent SLNB between 2010 and 2018 were retrospectively identified. Patient demographic, tumor, and imaging data was stratified by receipt of TcSC (n = 258) or TcTM (n = 133). Student's t test and χ2 test were used to compare characteristics and outcomes.Results: Both cohorts were similar in demographic, primary tumor characteristics, and total number of SLN identified (TcTM 3.56 vs. TcSC 3.28, p = 0.244). TcTM was associated with significantly shorter LS mapping times (51.8 vs. 195.1 min, p < 0.01). There was no significant difference in the number of patients with positive SLN (TcTM 11.3 vs. TcSC 17.4%, p = 0.109) and the FNR was similar between both groups (TcTM 25% vs. TcSC 22%).Conclusion: TcTM was associated with significantly shorter LS mapping time while identifying similar numbers of SLN. Our results support further study to ensure similar FNR and oncologic outcomes between agents.
- 17 November 2021
- Published by Wiley in Journal of Surgical Oncology
- Vol. 125 (4) , 712-718
How much time is enough? Sentinel lymph node mapping time depends on the radiotracer agent
Background: In 2014, technetium‐99m tilmanocept (TcTM) replaced technetium‐99m sulfur colloid (TcSC) as the standard lymphoscintigraphy (LS) mapping agent in melanoma patients undergoing sentinel lymph node biopsy (SLNB). The aim of this study was to examine differences in mapping time, intra‐operative identification of sentinel lymph node (SLN), and false negative rate (FNR) between patients who underwent SLNB with TcTM compared to TcSC.Methods: Patients who underwent SLNB between 2010 and 2018 were retrospectively identified. Patient demographic, tumor, and imaging data was stratified by receipt of TcSC (n = 258) or TcTM (n = 133). Student's t test and χ2 test were used to compare characteristics and outcomes.Results: Both cohorts were similar in demographic, primary tumor characteristics, and total number of SLN identified (TcTM 3.56 vs. TcSC 3.28, p = 0.244). TcTM was associated with significantly shorter LS mapping times (51.8 vs. 195.1 min, p < 0.01). There was no significant difference in the number of patients with positive SLN (TcTM 11.3 vs. TcSC 17.4%, p = 0.109) and the FNR was similar between both groups (TcTM 25% vs. TcSC 22%).Conclusion: TcTM was associated with significantly shorter LS mapping time while identifying similar numbers of SLN. Our results support further study to ensure similar FNR and oncologic outcomes between agents.
- Open Access
- 22 January 2021
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (7) , 3511
ASO Author Reflections: Gene Expression-Profiling and Implications for Adjuvant Therapy in Melanoma
- 22 January 2021
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (7) , 3511
Open AccessASO Author Reflections: Gene Expression-Profiling and Implications for Adjuvant Therapy in Melanoma
- 24 August 2020
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 111 (3) , 996-1003
Impact of Age on Surgical Outcomes for Locally Advanced Esophageal Cancer
- 24 August 2020
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 111 (3) , 996-1003
Impact of Age on Surgical Outcomes for Locally Advanced Esophageal Cancer